The antithrombotic profile of aspirin. Aspirin resistance, or simply failure?

[41] Weber A.A., Przytulski B., Schanz A., Hohlfeld T., Schror K., Towards a definition of aspirin resistance: A typological approach, Platelets, 13, pp. 37-40, (2002)

[42] Koksch M., Zeiger F., Wittig K., Siegemund A., Reininger C.B., Pfeiffer D., Ruehlmann C., Coagulation, fibrinolysis and platelet P-selectin expression in peripheral vascular disease, Eur. J. Vasc. Endovasc. Surg., 21, pp. 147-154, (2001)

[43] Weber A.A., Zimmermann K.C., Meyer-Kirchrath J., Schror K., Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance, Lancet, 353, (1999)

[44] Patrignani P., Sciulli M.G., Manarini S., Santini G., Cerletti C., Evangelista V., COX-2 is not involved in thromboxane biosynthesis by activated human platelets, J. Physiol. Pharmacol., 50, pp. 661-667, (1999)

[45] Kawasaki T., Ozeki Y., Igawa T., Kambayashi J., Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin, Stroke, 31, pp. 591-595, (2000)

[46] Macchi L., Christiaens L., Brabant S., Sorel N., Allal J., Mauco G., Brizard A., Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate, Thromb. Res., 107, pp. 45-49, (2002)

[47] Buchanan M.R., Brister S.J., Individual variation in the effects of ASA on platelet function: Implications for the use of ASA clinically, Can. J. Cardiol., 11, pp. 221-227, (1995)

[48] Andersen K., Hurlen M., Arnesen H., Seljeflot I., Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease, Thromb. Res., 108, pp. 37-42, (2002)

[49] Muller I., Besta F., Schulz C., Massberg S., Schonig A., Gawaz M., Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement, Thromb. Haemost., 89, pp. 783-787, (2003)

[50] Halushka M.K., Halushka P.V., Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2?, Circulation, 105, pp. 1620-1622, (2002)

[41] Weber A.A., Przytulski B., Schanz A., Hohlfeld T., Schror K., Towards a definition of aspirin resistance: A typological approach, Platelets, 13, pp. 37-40, (2002)

[42] Koksch M., Zeiger F., Wittig K., Siegemund A., Reininger C.B., Pfeiffer D., Ruehlmann C., Coagulation, fibrinolysis and platelet P-selectin expression in peripheral vascular disease, Eur. J. Vasc. Endovasc. Surg., 21, pp. 147-154, (2001)

[43] Weber A.A., Zimmermann K.C., Meyer-Kirchrath J., Schror K., Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance, Lancet, 353, (1999)

[44] Patrignani P., Sciulli M.G., Manarini S., Santini G., Cerletti C., Evangelista V., COX-2 is not involved in thromboxane biosynthesis by activated human platelets, J. Physiol. Pharmacol., 50, pp. 661-667, (1999)

[45] Kawasaki T., Ozeki Y., Igawa T., Kambayashi J., Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin, Stroke, 31, pp. 591-595, (2000)

[46] Macchi L., Christiaens L., Brabant S., Sorel N., Allal J., Mauco G., Brizard A., Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate, Thromb. Res., 107, pp. 45-49, (2002)

[47] Buchanan M.R., Brister S.J., Individual variation in the effects of ASA on platelet function: Implications for the use of ASA clinically, Can. J. Cardiol., 11, pp. 221-227, (1995)

[48] Andersen K., Hurlen M., Arnesen H., Seljeflot I., Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease, Thromb. Res., 108, pp. 37-42, (2002)

[49] Muller I., Besta F., Schulz C., Massberg S., Schonig A., Gawaz M., Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement, Thromb. Haemost., 89, pp. 783-787, (2003)

[50] Halushka M.K., Halushka P.V., Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2?, Circulation, 105, pp. 1620-1622, (2002)